MedTrace Logo

Memory Reconsolidation Blockade for Treating Drug Addiction

NCT01634347 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2017-05-15

No results posted yet for this study

Summary

The treatment involves administering propranolol, a medication indicated for treating high blood pressure. Propranolol is hypothesized to reduce the strength of drug or alcohol cravings (an integral factor involved in relapse), specifically when memories of substance use are recalled. In this study, propranolol or a placebo will be administered to patients participating in a drug or alcohol rehabilitation facility once a week over three or six weeks. After receiving propranolol or placebo, strong memories associated with substance craving are recalled by asking participants to read aloud a summary of a substance use experience. The investigators hypothesize that participants who receive propranolol will report fewer and less intense drug or alcohol cravings than participants who receive the placebo or treatment-as-usual.

Conditions

  • Substance Dependence

Interventions

DRUG

Propranolol and memory reactivation

Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.

DRUG

Placebo and memory reactivation

Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.

Sponsors & Collaborators

  • Douglas Mental Health University Institute

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01634347 on ClinicalTrials.gov